Literature DB >> 10656788

Selection of amino acid substitutions restoring activity of HIV-1 integrase mutated in its catalytic site using the yeast Saccharomyces cerevisiae.

V Parissi1, A B Caumont, V R de Soultrait, C Calmels, S Pichuantes, S Litvak, C H Dupont.   

Abstract

The integration of proviral DNA into the genome of the host cell is an essential step in the replication of retroviruses. This reaction is catalyzed by a viral-encoded enzyme, the integrase (IN). We have previously shown that human immunodeficiency virus type 1 (HIV-1) IN causes a lethal effect when expressed in yeast cells. This system, called yeast lethal assay, was used as a tool to study IN activity in a cellular context. The yeast lethal assay allowed the selection and characterization of mutations affecting both the lethal phenotype and the in vitro IN activities. IN mutants were produced by random PCR mutagenesis in an IN gene bearing the inactivating D116A mutation in the catalytic site. The corresponding D116A substituted IN does not lead to lethality in yeast. Subsequent selection of mutants able to restore the lethal effect of IN was carried out using the yeast lethal assay. We isolated three mutants presenting a restored phenotype. The mutated IN genes were sequenced and the corresponding proteins were purified to characterize their in vitro activities. The three mutants presented restoration of the in vitro strand transfer activity, while 3' processing was only partially restored.The three mutants differ from D116A IN by at least one amino acid substitution located in the N-terminal domain of the protein, outside of the active site. These new mutated HIV-1 INs may therefore allow a better understanding of the N-terminal domain function in the integration reaction. In addition, these results support our hypothesis that explains the lethal effect as a consequence of the nuclear damage caused by wild-type IN in yeast cells. These data also indicate that the yeast lethal assay can be used as a tool to study the retroviral integration mechanism in a cellular context and to select specific inhibitors. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656788     DOI: 10.1006/jmbi.1999.3416

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  5 in total

1.  A substitution in rous sarcoma virus integrase that separates its two biologically relevant enzymatic activities.

Authors:  Wesley M Konsavage; Stephen Burkholder; Malgorzata Sudol; Amy L Harper; Michael Katzman
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Biochemical and random mutagenesis analysis of the region carrying the catalytic E152 amino acid of HIV-1 integrase.

Authors:  C Calmels; V Richard de Soultrait; A Caumont; C Desjobert; A Faure; M Fournier; L Tarrago-Litvak; V Parissi
Journal:  Nucleic Acids Res       Date:  2004-03-03       Impact factor: 16.971

3.  d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers.

Authors:  Eileen Magbanua; Tijana Zivkovic; Björn Hansen; Niklas Beschorner; Cindy Meyer; Inken Lorenzen; Joachim Grötzinger; Joachim Hauber; Andrew E Torda; Günter Mayer; Stefan Rose-John; Ulrich Hahn
Journal:  RNA Biol       Date:  2012-12-12       Impact factor: 4.652

4.  Chromosomal integration of LTR-flanked DNA in yeast expressing HIV-1 integrase: down regulation by RAD51.

Authors:  S Desfarges; J San Filippo; M Fournier; C Calmels; A Caumont-Sarcos; S Litvak; P Sung; V Parissi
Journal:  Nucleic Acids Res       Date:  2006-11-07       Impact factor: 16.971

5.  Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication.

Authors:  Zaikun Xu; Yingfeng Zheng; Zhujun Ao; Martin Clement; Andrew J Mouland; Ganjam V Kalpana; Pierre Belhumeur; Eric A Cohen; Xiaojian Yao
Journal:  Retrovirology       Date:  2008-11-14       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.